Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction [ATAC-seq]

ABSTRACT: ATACseq analysis of tumor-infiltrating CD8 T cells encountering high (F6) or low (D4) affinity tumor antigen.

ORGANISM(S): Mus musculus

PROVIDER: GSE141816 | GEO | 2021/12/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction [RNA-seq]

Project description:RNA-seq analysis of tumor-specific CD8 T cells encountering tumor antigens with varying TCR/pMHC affinity.

2021-12-11 | GSE141817 | GEO

TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-12-09 | GSE141818 | GEO

TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction

Project description:TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction

| PRJNA594907 | ENA

TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction [RNA-seq]

Project description:TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction [RNA-seq]

| PRJNA594911 | ENA

TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction [ATAC-seq]

Project description:TCR affinity defines tumor-specific CD8 T cell differentiation and dysfunction [ATAC-seq]

| PRJNA594912 | ENA

TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.

Project description:T cell receptor (TCR) signal strength is a key determinant of T cell responses. We developed a cancer mouse model in which tumor-specific CD8 T cells (TST cells) encounter tumor antigens with varying TCR signal strength. High-signal-strength interactions caused TST cells to up-regulate inhibitory receptors (IRs), lose effector function, and establish a dysfunction-associated molecular program. TST cells undergoing low-signal-strength interactions also up-regulated IRs, including PD1, but retained a cell-intrinsic functional state. Surprisingly, neither high- nor low-signal-strength interactions led to tumor control in vivo, revealing two distinct mechanisms by which PD1hi TST cells permit tumor escape; high signal strength drives dysfunction, while low signal strength results in functional inertness, where the signal strength is too low to mediate effective cancer cell killing by functional TST cells. CRISPR-Cas9-mediated fine-tuning of signal strength to an intermediate range improved anti-tumor activity in vivo. Our study defines the role of TCR signal strength in TST cell function, with important implications for T cell-based cancer immunotherapies.

| S-EPMC8704919 | biostudies-literature

Coreceptor affinity for MHC defines peptide specificity requirements for TCR interaction with coagonist peptide-MHC.

Project description:Recent work has demonstrated that nonstimulatory endogenous peptides can enhance T cell recognition of antigen, but MHCI- and MHCII-restricted systems have generated very different results. MHCII-restricted TCRs need to interact with the nonstimulatory peptide-MHC (pMHC), showing peptide specificity for activation enhancers or coagonists. In contrast, the MHCI-restricted cells studied to date show no such peptide specificity for coagonists, suggesting that CD8 binding to noncognate MHCI is more important. Here we show how this dichotomy can be resolved by varying CD8 and TCR binding to agonist and coagonists coupled with computer simulations, and we identify two distinct mechanisms by which CD8 influences the peptide specificity of coagonism. Mechanism 1 identifies the requirement of CD8 binding to noncognate ligand and suggests a direct relationship between the magnitude of coagonism and CD8 affinity for coagonist pMHCI. Mechanism 2 describes how the affinity of CD8 for agonist pMHCI changes the requirement for specific coagonist peptides. MHCs that bind CD8 strongly were tolerant of all or most peptides as coagonists, but weaker CD8-binding MHCs required stronger TCR binding to coagonist, limiting the potential coagonist peptides. These findings in MHCI systems also explain peptide-specific coagonism in MHCII-restricted cells, as CD4-MHCII interaction is generally weaker than CD8-MHCI.

| S-EPMC3754861 | biostudies-literature

eRNA: A graphic user interface-based tool for RNA sequencing data analysis [microRNA-Seq]

Project description:we performed RNA sequencing analysis using 7 human plasma samples and evaluated efficiency and accuracy of eRNA on miRNA-seq data analysis. We sequenced microRNAs from the 7 human tissue samples with replicates (A1/A8, B2/B9, C3/C10, D4/D11, E5/E12, F6/F13, G7/G14) using NEBNext Multiplex Small RNA library Prep Set from New England Biolab (NEB). After that, we identified miRNAs in these plasma samples against known human matured miRNAs.

2014-06-01 | E-GEOD-53451 | biostudies-arrayexpress

Temporally resolved single-cell transcriptomics defines immune dysfunction trajectories in glioblastoma

Project description:Immune cells sense their environment and adapt their state. Deciphering cellular trajectories unfolding over time is fundamental for understanding biology. Empirical in vivo genomic technologies measuring both cell state and time are lacking. Here, we present Zman-seq, a single-cell technology tracking transcriptomic dynamics across time by introducing fluorescent time stamps into immune cells. We applied Zman-seq to resolve immune cell state-transitions of the dysfunctional tumor immune microenvironment (TME) of glioblastoma (GBM). By measuring the exposure time of infiltrating immune cells in the TME, Zman-seq defines the cellular and molecular trajectories underlying immune incompetence in GBM. Within 24 hours, cytotoxic NK cells transitioned to a dysfunctional program regulated by Tgfb1, while monocytes differentiated into immunosuppressive macrophages in 36-48 hours. Anti-TREM2 antagonistic antibody reshaped the TME by redirecting monocytes to pro-inflammatory macrophages. Zman-seq is a broadly applicable technology enabling empirical measurements of differentiation trajectories guiding the development of more efficacious immunotherapies.

2023-12-21 | GSE232040 | GEO

ATACseq profiling of various TOX+ and TOX- tumor-infiltrating CD8 T cells

Project description:ATACseq profiling of various TOX+ and TOX- tumor-infiltrating CD8 T cells

| PRJNA523939 | ENA